TriangleCabazitaxel and carboplatin (NCT06738303)
Cabazitaxel and carboplatin trial for Metastatic Prostate Cancer (NCT06738303). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged nineteen or older with PSMA-positive, metastatic castration-resistant prostate adenocarcinoma after androgen-receptor pathway treatment. At least one specified aggressive-disease feature is required. Previous docetaxel is optional.
The idea: randomly compare cabazitaxel plus carboplatin with lutetium-177 PSMA-617. The chemotherapy disrupts cell division and damages DNA. The radioligand delivers radiation to PSMA-bearing cells. Chemotherapy is given every three weeks; radioligand infusions occur every six weeks. Researchers compare PSA responses.
This phase 2 study plans 44 patients. Pedro Barata leads one recruiting Cleveland site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.